There is no evidence that PUFA supplementation in infancy has an effect on infant or childhood allergy , asthma , dermatitis/eczema or food allergy .
However , the quality of evidence was very low .
There was insufficient evidence to determine an effect on allergic rhinitis
BACKGROUND Early dietary intakes may influence the development of allergic disease .
It is important to determine if dietary polyunsaturated fatty acids ( PUFAs ) given as supplements or added to infant formula prevent the development of allergy .
OBJECTIVES To determine the effect of higher PUFA intake during infancy to prevent allergic disease .
Oral administration of docosahexaenoic acid attenuates interleukin-1β response and clinical course of septic neonates.
OBJECTIVE To analyze cytokine responses and the clinical course of septic neonates orally supplemented with docosahexaenoic acid as well as to evaluate fatty acid incorporation into leukocytes . METHODS A quasiexperimental study was conducted in neonates who developed sepsis following a surgical procedure . Selected neonates were r and omly assigned to receive 100 mg docosahexaenoic acid ( G-DHA ) daily or olive oil ( G-OO ) as placebo for 14 d throughout a sepsis episode . At selection ( baseline ) , blood sample s were obtained to determine interleukin-1 (IL-1)β , interleukin-6 ( IL-6 ) , and tumor necrosis factor-α as well as the leucocyte fatty acid profile . Measurements were repeated at 7 ( D7 ) and 14 d ( D14 ) of follow-up . Within- and between-group comparisons were conducted with parametric statistics after logarithmic transformation . Repeated measurement analyses with a general linear model procedure were used , adjusting according to human milk intake , use of anti-inflammatory drugs , and nutritional status . RESULTS Sixty-three neonates were included : 29 in G-DHA group and 34 in G-OO group . Although decreases of cytokines during hospitalization were similar in both groups , there was a greater decrease of IL-1β in the G-DHA group than in the G-OO group after adjusting by confounders ( P = 0.028 ) . Leukocyte docosahexaenoic acid increased from 4.96 ± 2.96 at baseline to 5.52 ± 3.05 and 5.92 ± 2.8 at D7 and D14 , respectively , in the G-DHA group ( P = 0.044 ) . Illness severity was inversely associated with the proportion of docosahexaenoic acid in leukocytes throughout follow-up ( P = 0.034 ) . CONCLUSIONS Oral supplementation with docosahexaenoic acid to neonates  attenuates IL-1β response and the clinical course of sepsis . This may be an additional strategy to further benefit ill neonates even if they are not c and i date s for parenteral nutrition
There is no evidence that PUFA supplementation in infancy has an effect on infant or childhood allergy , asthma , dermatitis/eczema or food allergy .
However , the quality of evidence was very low .
There was insufficient evidence to determine an effect on allergic rhinitis
BACKGROUND Early dietary intakes may influence the development of allergic disease .
It is important to determine if dietary polyunsaturated fatty acids ( PUFAs ) given as supplements or added to infant formula prevent the development of allergy .
OBJECTIVES To determine the effect of higher PUFA intake during infancy to prevent allergic disease .